Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody,
L
Linda DiMeglio, MD
Primary Investigator
Overview
(THIS IS AN EXTENSION STUDY)
To evaluate the long-term safety of teplizumab in participants who previously completed the PRV-031-001 (PROTECT) study for an additional 42 months of follow-up
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Type 1 Diabetes
-
Age: - 100 Years
-
Gender: All
Inclusion Criteria:
- "children and adolescents"
Exclusion Criteria:
Updated on
27 Apr 2024.
Study ID: 100262, PENDO-PROVENTION-PROTECT-OLE
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
